Statins increase lymphoid malignancy rates by 124%

This study was published in Cancer Science 2006 Feb;97(2):133-8

Study title and authors:

Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies.

Iwata H, Matsuo K, Hara S, Takeuchi K, Aoyama T, Murashige N, Kanda Y, Mori S, Suzuki R, Tachibana S, Yamane M, Odawara M, Mutou Y, Kami M.

Department of Cardiology, Toranomon Hospital, Tokyo 105-8470, Japan.

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/16441424

The study examined the association between statin use and development of lymphoid malignancies. Statin use of 221 cases with proven lymphoid malignancies (lymphoma and myeloma), from Toranomon Hospital (Tokyo, Japan) was compared with statin use of 879 patients without malignancies from the same hospital.

The study found there was a 124% higher frequency of statin use among patients with lymphoid malignancies in comparison with the other patients.